Clinical trials: Solid Tumor, Adult, open to volunteers
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Solid Tumors With FGFR2 Alterations, Adult
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
- Trial name
- NCT06378593
- Testing
- 3HP-2827
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- 3H (Suzhou) Pharmaceuticals Co., Ltd.
Breast Carcinoma, Malignant Digestive System Neoplasm
Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital.
- Conditions
- Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
- Trial name
- NCT07606287
- Testing
- Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Solid Tumours
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
- Trial name
- NCT07160725
- Testing
- BMS-986517, Pumitamig
- Where
- 20 sites in United States, China and 3 more
- Volunteers
- 540 people
- Sponsor
- Bristol-Myers Squibb
Pancreas Cancer, CAR-T Cell Therapy
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
- Trial name
- NCT05779917
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae
Advanced EGFR Positive Solid Tumor
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to…
- Trial name
- NCT04412616
- Testing
- ZZ06
- Where
- 5 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Advanced Solid Cancer
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
- Trial name
- Solid Tumors (NCT07265921)
- Testing
- SIM0609 for injection, dose expansion of SIM0609 in CRC, dose expansion of SIM0609 in GC/GEJC cohort
- Where
- 6 sites in China
- Volunteers
- 232 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or…
- Trial name
- NCT06874335
- Testing
- BHV-1530, Cemiplimab
- Where
- 17 sites in United States
- Volunteers
- 140 people
- Sponsor
- Biohaven Therapeutics Ltd.
Solid Tumor, Adult
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
The NRG1 gene is located on chromosome 8 (8p12 region) and encode NRG1. NRG1 gene is translated to generate six different proteins (I-VI) and at least 31 isoforms.
- Trial name
- NCT06383884
- Testing
- Patritumab Deruxtecan
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Solid Tumor, Adult, Lymphoma
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine…
- Conditions
- Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
- Trial name
- NCT05631886
- Testing
- TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Background: Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
- Conditions
- Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
- Trial name
- NCT02390752
- Testing
- TURALIO(R)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Adult Solid Tumor, Advanced Solid Tumor
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic…
- Conditions
- Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT05752552
- Testing
- DO-2
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 55 people
- Sponsor
- DeuterOncology
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2…
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer
- Trial name
- NCT07612891
- Testing
- INV-6452
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.